Currently researchers and veterinarians at Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech are studying a treatment for sarcoids in equines and have found that H-FIRE is effective at controlling the tumor's growth.
Research making advances in horse health
A new treatment called H-FIRE, which stands for high-frequency irreversible electroporation involves a long needle that delivers a short burst of electricity into specific places in the horse's sarcoid tumor.
The new treatment is called H-FIRE, which stands for high-frequency irreversible electroporation. It involves a long needle that delivers a short burst of electricity into specific places in the sarcoid tumor.
"Sarcoids are locally invasive skin tumors that we deal with often in equine medicine," said Dr. J. Michael Cissell, the veterinarian leading the experitreatment. "Due to sarcoids' invasiveness, simple removal is not always effective even when we remove wide margins of tissue that may be involved."
In all, seven horses have been clinical trial patients for H-FIRE for various types of tumors. Although sarcoids just invade skin and don't affect other organs of the body, they very often recur, can become worse with treatment, and can appear in other areas than the initial site.
"Management of sarcoids can be difficult even though there are several treatment protocols available," according to Cissell. "All of the currently used treatments have their limitations. Adding to the removal problems is the fact that sometimes just attempting sarcoid treatment can activate the tumor and cause it to grow."
The bioengineering team that developed H-FIRE and the veterinary team that is using it in the equine clinical trials plan to start trying it on melanomas and squamous cell carcinomas, both malignant tumors, that both horses and humans can develop. To do this and to refine the treatment on horses with sarcoids, they need a larger generator. The generator delivers the electric pulses and must be custom made. Funding for that currently isn't available, according to Rafael Davalos, who leads the research team from the Virginia Tech-Wake Forest University School of Biomedical Engineering and Science.
"One of the challenges is the generator isn't as powerful as we'd like for a horse," said Davalos. "With a larger one, we wouldn't have to do as many treatments. A custom-built pulse generator would cost $50,000 to $60,000."
The horse Paco is the first to undergo the experimental treatments and has undergone all of the treatments currently available to fight sarcoids. His tumor first appeared about the size of a silver dollar on his right jawline when he was about 4 years old. It didn't become a problem until about two years later when he scraped it on a tree while he and his owner were on a trail ride.
"Every time we'd treat the sarcoid with traditional methods, it came back as big as a fist in a week," Powell said. The tumor has continued to recur although sometimes in a spot adjacent to the last one treated.
The needle that carries the pulsating 800-850-volt electric charge to the tumor stays in each spot three minutes and then is re-inserted about a centimeter away. It doesn't burn the horse because it isn't a continuous charge and it's only focused on the tumor cells. The electric pulse is one burst of energy per second with each burst lasting about 100 microseconds.
Paulo Garcia, a member of the bioengineering research team who was monitoring Paco's vital signs throughout a recent treatment, said that the actual charge feels like a mosquito bite. A local anesthetic is given before the treatment.
Cissell and Davalos said being able to perform this treatment with just local anesthesia so the horse can remain standing is one advantage of H-FIRE. They believe that this treatment method may be applicable for other types of tumors and diseases in which it's necessary for the patient awake to measure effectiveness of a procedure.
H-FIRE isn't available for commercial use now and the cost to the public once it is hasn't been determined. However, more openings for the clinical test are available. The patients for the trial are those horses for whom traditional treatments have been ineffective. The veterinarians and the biomedical engineering team hope to test the new treatment on 15 more horses in the next year.